the british swedish drug company astrazeneca said it earned 706 million in the second quarter topping expectations as revenue grew 32 percent the company is planning a series of blockbuster drugs as its best selling prilosec ulcer treatment faces competition from generic rivals possibly this year astrazeneca said in april that investment in new drugs including nexium for ulcers introduced earlier this year and the anti cholesterol drug crestor to be introduced in 2002 would reduce second quarter profit alan cowell nyt

